OliX Pharmaceuticals Inc.
History
| Year | Detail |
|---|---|
| 2010 | The company was founded by Dong-ki Lee on February 26, 2010, and is headquartered in Suwon-si, South Korea. |
| 2013 | OliX collaborated with Hugel Inc. to treat hypertrophic scarring. |
| 2017 | The company moved its headquarters to Suwon, near Seoul in South Korea. |
| 2019 | The company collaborated with Théa Open Innovation, a sister company of Laboratoires Théa S.A.S, an independent pharmaceutical company in Europe dedicated to ophthalmology, to develop and commercialize OLX301A, a novel treatment for dry and wet age-related macular degeneration. |
| 2020 | The company signed an agreement with LGC Biosearch Technologies to accelerate the production of Asymmetric siRNA for the treatment of Sub-Retinal Fibrosis and Wet Macular Degeneration. |
| 2021 | OliX Pharmaceuticals launched a new subsidiary, mCureX Therapeutics, Inc., to develop mRNA Vaccines and Therapeutics. |
| 2021 | OliX Pharmaceuticals and PCI Biotech collaborated to combine OliX asiRNA and PIC Biotech fimaNAc Technologies. |
| 2021 | Hansoh Pharma, a biopharmaceutical company, and OliX Pharmaceuticals collaborated to develop and commercialize siRNA Therapeutics in Greater China. |
| 2023 | The company signed a memorandum of understanding (MOU) with DynamiCure Biotechnology to develop ADC Immunotherapy using RNA at the Korea-US Digital·BioHealth Business Forum. |
BCC Research Beacon 